Market Overview

Gilead Announces Positive Phase 3 HCV Treatment Results in Patients Co-Infected With HIV

Gilead Sciences (NASDAQ: GILD) today announced results from a Phase
3 study, PHOTON-1, evaluating the investigational once-daily nucleotide
analogue sofosbuvir for the treatment of chronic hepatitis C virus (HCV)
infection among patients co-infected with HIV. In the trial, 76 percent
(n=87/114) of genotype 1 HCV treatment-naïve patients receiving 24 weeks
of an all-oral, interferon-free regimen of sofosbuvir plus ribavirin
(RBV) achieved a sustained virologic response 12 weeks after completing
therapy (SVR12). Patients who achieve SVR12 are considered cured of HCV
infection. These data will be presented this week during the 64th
Annual Meeting of the American Association for the Study of Liver
Diseases (The Liver Meeting 2013) in Washington, D.C.

Up to one-third of people

See full press release

Posted-In: News Guidance FDA Global

 

Related Articles (GILD)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters

Benzinga Professional